Founded in 2002, Amneal is headquartered in Bridgewater, New Jersey. The company operates 6 manufacturing facilities in the United States, 4 in India, 1 in Ireland, a dedicated packaging plant in New Jersey and over 300,000 square feet of space among three distribution centers in Glasgow, Kentucky. 

Amneal has grown organically and through M&A to become one of the leading US generic pharmaceutical companies. Today, Amneal markets a portfolio of more than 200 generic product families, including complex dosage forms in a broad range of therapeutic areas. The company also markets a portfolio of branded pharmaceutical products focused primarily on central nervous system disorders, hypothyroidism and parasitic infections.

Amneal is renowned for its quality culture—one of the core pillars of its success. Employees work to consistently meet or exceed quality, industry and global regulatory standards. For each member of the team, “Quality” is a mindset that helps the whole achieve their goal to make healthy possible. Every day, across all roles and functions, Amneal team members embrace the idea that “Quality begins with me.” This call to action is enhanced by a long-standing commitment to delivering trust, integrity, and value.

Earlier this year, Amneal launched its generic version of Exelon® Patch (rivastigmine transdermal system). The product was Amneal’s first transdermal product. It was followed shortly by its second, a generic version of Vivelle-DOT® (estradiol transdermal system). Both demonstrate the company’s commitment to develop and bring to market complex generic products.

Within its extensive manufacturing network, Amneal has substantially completed the renovation and expansion of its flagship Brookhaven, New York, production facility, allowing for additional capacity. The company also recently completed construction of a new, 80,000-square-foot distribution facility in Glasgow, Kentucky, which will accommodate Amneal’s growing product portfolio. 

Amneal has distinguished itself within the generic industry through its diversified pipeline of complex, high-value generic products. In 2018, Amneal led the US generics industry in both approvals and launches, including 62 Abbreviated New Drug Application (ANDA) approvals, 10 tentative approvals and 42 new products launched. Approximately 37% of the company’s new product launches were from injectable, topical or liquid products, further diversifying its portfolio of more than 200 generic products.  The company is on track to launch as many as 50 new products this year. 

For more information, visit amneal.com.